Carregant...
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can also trigger immune-related adverse events. Checkpoint inhibitor pneumonitis (CIP) has been reported to have a morbidit...
Guardat en:
| Publicat a: | Cancer Biol Med |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Compuscript
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7476083/ https://ncbi.nlm.nih.gov/pubmed/32944393 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2020.0102 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|